Eli Lilly vs. The Grey Market: The Future of Peptide Medicine

Eli Lilly’s fight over retatrutide may be about much more than one obesity drug.I’ve been covering retatrutide since early 2023, and since late 2024 I’ve been closely following the legal fight over whether reta should be treated as a biologic. From the beginning, I’ve argued that this case could have consequences far beyond retatrutide itself.In this episode, I break down the growing unauthorized retatrutide market, the serious adverse events and death reports now entering the conversation, Lilly’s repeated legal actions against sellers, the restricted Seventh Circuit filings, and new context I’ve heard from someone connected to senior HHS policy discussions.The biggest question is no longer simply what happens to retatrutide. It’s whether this case could help shape how future peptide medicines are classified, regulated, and protected.I’m continuing to track the Seventh Circuit docket and work on the restricted filings. If those documents become available or I can independently confirm what is in them, subscribers at obesity.news and OnThePen.com will hear about it first.This episode is brought to you by VoaFit and Trilogiii Daily Essentials. Check the links in the show notes, and use code OTP10 for Trilogiii.Visit Trilogiii: https://triii.life/tiers/daily-essentials?utm_source=onthepen&utm_medium=influencer&utm_campaign=dave_knappVisit Voafit: https://www.voafit.com/otp

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(217)

NEW FDA ZEPBOUND WARNING!

VOTE FOR DAVE: https://tophost.org/2026/david-knappThe FDA just issued a NEW eye warning for EVERY GLP-1 medication, including Ozempic, Wegovy, Mounjaro, and Zepbound. But how worried should patients ...

10 Nov 28min

Novo's Next Weight Loss Pill Isn't a GLP-1, And That's HUGE

What if the next big breakthrough in obesity medicine isn't a GLP-1 at all?Novo Nordisk is developing an experimental oral weight-loss medication called LX9851, an ACSL5 inhibitor that targets an enti...

4 Nov 23min

Retatrutide Phase 3 Results: What You Need to Know

Retatrutide’s New Phase 3 Data, CagriSema in Menopause, and the Growing GLP‑1 Access CrisisHost Dave Knapp recaps major obesity-drug updates, focusing on Eli Lilly’s triple agonist retatrutide and Nov...

27 Okt 31min

GLP-1 Recall Update: Why You Need to Check Your Vials

Specific lots of compounded tirzepatide have been recalled over sterility concerns, another pharmacy recently recalled compounded semaglutide after particulate matter was identified, patients have rep...

20 Okt 27min

Ozempic & Zepbound Are Changing America in Ways Nobody Expected

Zepbound isn’t just changing people’s weight. GLP-1 medications are beginning to change America itself.Restaurants are rethinking what they serve. Grocery baskets are changing. Food companies are payi...

7 Okt 24min

They TRIPLED Wegovy Dose, Does it Beat Zepbound?

This week on On The Pen, The Weekly Dose, we break down one of the biggest weeks in obesity medicine coming out of EASD 2026.Eli Lilly says Zepbound may still outperform Wegovy 7.2 mg, even after Novo...

1 Okt 30min

Retatrutide in Court, Compound GLP-1 Under Fire

This week on On The Pen, The Weekly Dose Podcast, retatrutide heads into a major federal court fight as the Department of Justice gives FDA fresh legal ammunition just days before oral argument.At the...

22 Sep 29min